-
Je něco špatně v tomto záznamu ?
The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment
D. Grega, J. Kolář
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- biologické přípravky * terapeutické užití MeSH
- finanční stres MeSH
- lidé MeSH
- náklady na zdravotní péči MeSH
- osobní újma zaviněná nemocí MeSH
- revmatoidní artritida * farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVES: This article aimed to count and compare treatment's direct (only biological drugs) and indirect (loss of productivity) costs in patients with rheumatoid arthritis from 2019 to 2021. METHODS: The friction cost approach was used to establish indirect costs. Elasticity factor values and friction period for the Slovak Republic from 2019 to 2021 were determined. Direct drug costs were calculated based on average prices from 2019 to 2021 and the number of dispensed medication packages. RESULTS: The average productivity loss reached €2984.54 in 2019, €3338.46 in 2020, and €3154.01 in 2021. Total indirect costs include productivity loss and sick pay, and from 2019 to 2021 came the values of €8.4 million, €10.1 million, and €8.1 million, respectively. CONCLUSIONS: Indirect costs were almost 2.5 to 3 times lower than the biological and targeted treatment costs.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006982
- 003
- CZ-PrNML
- 005
- 20240423155626.0
- 007
- ta
- 008
- 240412e20231114xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.vhri.2023.10.001 $2 doi
- 035 __
- $a (PubMed)37972429
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Grega, Dominik $u Department of Applied Pharmacy, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic. Electronic address: gregad@pharm.muni.cz
- 245 14
- $a The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment / $c D. Grega, J. Kolář
- 520 9_
- $a OBJECTIVES: This article aimed to count and compare treatment's direct (only biological drugs) and indirect (loss of productivity) costs in patients with rheumatoid arthritis from 2019 to 2021. METHODS: The friction cost approach was used to establish indirect costs. Elasticity factor values and friction period for the Slovak Republic from 2019 to 2021 were determined. Direct drug costs were calculated based on average prices from 2019 to 2021 and the number of dispensed medication packages. RESULTS: The average productivity loss reached €2984.54 in 2019, €3338.46 in 2020, and €3154.01 in 2021. Total indirect costs include productivity loss and sick pay, and from 2019 to 2021 came the values of €8.4 million, €10.1 million, and €8.1 million, respectively. CONCLUSIONS: Indirect costs were almost 2.5 to 3 times lower than the biological and targeted treatment costs.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a finanční stres $7 D000086522
- 650 _2
- $a osobní újma zaviněná nemocí $7 D017281
- 650 _2
- $a náklady na zdravotní péči $7 D017048
- 650 12
- $a revmatoidní artritida $x farmakoterapie $7 D001172
- 650 12
- $a biologické přípravky $x terapeutické užití $7 D001688
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kolář, Jozef $u Department of Applied Pharmacy, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic
- 773 0_
- $w MED00196873 $t Value in health regional issues $x 2212-1102 $g Roč. 40 (20231114), s. 13-18
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37972429 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155623 $b ABA008
- 999 __
- $a ok $b bmc $g 2081146 $s 1216749
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 40 $c - $d 13-18 $e 20231114 $i 2212-1102 $m Value in health regional issues $n Value Health Reg Issues $x MED00196873
- LZP __
- $a Pubmed-20240412
